Analyst Summary
- Tiziana Life Sciences has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement.
- The company was previously notified on January 29, 2025, that it was not in compliance with the minimum bid price rule.
- To regain compliance, the company maintained a minimum closing bid price of $1.00 or more for at least ten consecutive trading days, which was met on March 12, 2025.
- Tiziana’s lead candidate, intranasal foralumab, is currently being studied in a Phase 2a trial for non-active secondary progressive multiple sclerosis.
- The FDA has recently allowed an additional 20 patients to be enrolled in the Expanded Access program for Foralumab.